Cidara Therapeutics, Inc.CDTXNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average, modest growth trend.
Left:
||||
Year-over-year research & development expense growth
Latest
326.41%
↑ 391% above average
Average (9y)
66.49%
Historical baseline
Range
High:326.41%
Low:-52.51%
CAGR
+3.0%
Modest growth trend
| Period | Value |
|---|---|
| 2024 | 326.41% |
| 2023 | -52.51% |
| 2022 | 5.91% |
| 2021 | 7.45% |
| 2020 | 46.59% |
| 2019 | -5.58% |
| 2018 | 14.76% |
| 2017 | 19.96% |
| 2016 | 52.07% |
| 2015 | 249.85% |